Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

AZD 4205

Drug Profile

AZD 4205

Alternative Names: AZD-4205; DZD4205

Latest Information Update: 04 Oct 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator AstraZeneca
  • Developer Dizal Pharmaceutical
  • Class Acetamides; Anti-inflammatories; Antineoplastics; Indoles; Piperazines; Pyrazoles; Pyrimidines; Small molecules
  • Mechanism of Action Janus kinase 1 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Non-small cell lung cancer; Peripheral T-cell lymphoma
  • Phase I Autoimmune disorders; Inflammatory bowel diseases

Most Recent Events

  • 10 Sep 2019 Phase-I/II clinical trials in Peripheral T-cell lymphoma (Monotherapy, Second-line therapy or greater, In adults, In the elderly) in South Korea (PO) (NCT04105010)
  • 30 Apr 2019 Chemical structure information added
  • 25 Apr 2019 Dizal Pharmaceutical plans a global phase I trial for Inflammatory bowel disease in 2019 (Company pipeline, April 2019)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top